Background to and Management of Treatment-Related Bone Loss in Prostate Cancer

[1]  K. Carlström,et al.  Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens , 1995, Calcified Tissue International.

[2]  C. Tyrrell,et al.  Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate , 1994, Calcified Tissue International.

[3]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[4]  S. Cerutti,et al.  Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. , 2002, The Journal of urology.

[5]  W. Pitts,et al.  Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer. , 2002, The Journal of urology.

[6]  L. Dogliotti,et al.  Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. , 2001, The Journal of urology.

[7]  M. Resnick,et al.  Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. , 2001, The Journal of urology.

[8]  E. Orwoll.  Androgens: Basic Biology and Clinical Implication , 2001, Calcified Tissue International.

[9]  P. Kantoff,et al.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. , 2001, The New England journal of medicine.

[10]  S. Adami,et al.  Alendronate for the Treatment of Osteoporosis in Men , 2001, Calcified Tissue International.

[11]  P. de Souza,et al.  The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade , 2001, Cancer.

[12]  H. Daniell,et al.  Osteoporosis due to androgen deprivation therapy in men with prostate cancer. , 2001, Urology.

[13]  S. Ho,et al.  Clinical review 134: The endocrinology of prostate cancer. , 2001, The Journal of clinical endocrinology and metabolism.

[14]  P. Kantoff,et al.  Low bone mineral density in hormone‐naïve men with prostate carcinoma , 2001, Cancer.

[15]  R. Parker,et al.  Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. , 2001, The Journal of clinical endocrinology and metabolism.

[16]  J. Body,et al.  Zoledronic acid. Author's Reply , 2001 .

[17]  D. Meltzer,et al.  Patterns of prostate cancer treatment by clinical stage and age. , 2001, American journal of public health.

[18]  M. Terris,et al.  Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. , 2001, Urology.

[19]  P. Abrahamsson.  Treatment of Locally Advanced Prostate Cancer – A New Role for Antiandrogen Monotherapy? , 2000, European Urology.

[20]  T. Tammela,et al.  Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. , 2000, The Journal of urology.

[21]  L. Dogliotti,et al.  Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. , 2000, The Journal of urology.

[22]  A. Furuta,et al.  Incidence of bone fracture in patients receiving luteinizing hormone‐releasing hormone agonists for prostate cancer , 2000, BJU international.

[23]  C C Glüer,et al.  The use of bone densitometry in clinical practice. , 2000, Bailliere's best practice & research. Clinical endocrinology & metabolism.

[24]  Crawford,et al.  Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.

[25]  M. Resnick,et al.  Analysis of recent trends in prostate cancer incidence and mortality , 2000, The Prostate.

[26]  S. Reddy,et al.  1,25‐Dihydroxyvitamin D3 Hypersensitivity of Osteoclast Precursors from Patients with Paget's Disease , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  B. Tombal,et al.  Immediate vs. delayed androgen deprivation for prostate cancer , 2000 .

[28]  D. Ferguson,et al.  Progressive osteoporosis during androgen deprivation therapy for prostate cancer. , 2000, The Journal of urology.

[29]  R. Stege.  Potential side‐effects of endocrine treatment of long duration in prostate cancer , 2000, The Prostate. Supplement.

[30]  P. Delmas.  Markers of Bone Turnover for Monitoring Treatment of Osteoporosis with Antiresorptive Drugs , 2000, Osteoporosis International.

[31]  J. Adams,et al.  Do Men and Women Fracture Bones at Similar Bone Densities? , 2000, Osteoporosis International.

[32]  J. Stepan,et al.  Prediction of Bone Loss in Postmenopausal Women , 2000, Osteoporosis International.

[33]  J. Manola,et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.

[34]  I. Reid.  Pharmacological Management of Osteoporosis in Postmenopausal Women , 1999, Drugs & aging.

[35]  John T. Wei,et al.  Androgen deprivation therapy for prostate cancer results in significant loss of bone density. , 1999, Urology.

[36]  S. Cerutti,et al.  Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. , 1999, Clinical chemistry.

[37]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[38]  T. Kitamura,et al.  Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation , 1999, Cancer.

[39]  J. Sibilia,et al.  Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. , 1999, The Journal of urology.

[40]  J. Kanis,et al.  Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  T. Diamond,et al.  The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma , 1998, Cancer.

[42]  H. Daniell,et al.  Testicular atrophy in therapeutic orchiectomy specimens from men with prostate carcinoma , 1998, Cancer.

[43]  E. Small.  Prostate Cancer , 1998, Drugs & aging.

[44]  M. Barry,et al.  Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices. , 1998, The Journal of urology.

[45]  N. Mauras,et al.  Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. , 1998, The Journal of clinical endocrinology and metabolism.

[46]  G E Dallal,et al.  Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. , 1997, The New England journal of medicine.

[47]  M. Piérart,et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.

[48]  G. Duchesne,et al.  Androgens and prostate cancer: biology, pathology and hormonal therapy. , 1997, European journal of cancer.

[49]  R. A. Jones,et al.  Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. , 1997, British journal of urology.

[50]  H. Daniell.  Osteoporosis after orchiectomy for prostate cancer. , 1997, The Journal of urology.

[51]  S. Graham,et al.  Bone fractures associated with luteinizing hormone‐releasing hormone agonists used in the treatment of prostate carcinoma , 1997, Cancer.

[52]  G. Hortobagyi,et al.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.

[53]  Kenneth K Wang,et al.  Esophagitis associated with the use of alendronate. , 1996, The New England journal of medicine.

[54]  L. Dogliotti,et al.  Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. , 1996, British Journal of Cancer.

[55]  M. Kovacs,et al.  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.

[56]  E. Crawford,et al.  Estrogens in the treatment of prostate cancer. , 1995, The Journal of urology.

[57]  G. Kennealey,et al.  Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. , 1995, Urology.

[58]  R. Heaney.  Optimal calcium intake. , 1995, JAMA.

[59]  T. Diamond,et al.  Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. , 1995, The Journal of urology.

[60]  A. Amorosi,et al.  Prostate Cancer: Population-Based Survival Rates in Central Italy , 1995, Tumori.

[61]  S. Ralston,et al.  Pathogenesis and management of cancer associated hypercalcaemia. , 1994, Cancer surveys.

[62]  E. Seeman.  Osteoporosis in men: epidemiology, pathophysiology, and treatment possibilities. , 1993, The American journal of medicine.

[63]  Denis Lj.  Staging and prognosis of prostate cancer. , 1993 .

[64]  N. Clarke,et al.  The effects of orchidectomy on skeletal metabolism in metastatic prostate cancer. , 1993, Scandinavian journal of urology and nephrology.

[65]  H. Fleisch.  Bisphosphonates , 2012, Drugs.

[66]  F. Singer.  Paget's Disease of Bone: Clinical Assessment, Present and Future Therapy , 1991 .

[67]  J. Kanis,et al.  Treatment of Paget’s Disease with the New Bisphosphonates , 1991 .

[68]  J. Brody,et al.  Hip fracture incidence among the old and very old: a population-based study of 745,435 cases. , 1990, American journal of public health.

[69]  J. Reginster,et al.  PREVENTION OF POSTMENOPAUSAL BONE LOSS BY TILUDRONATE , 1989, The Lancet.

[70]  D. Baylink,et al.  Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. , 1989, The Journal of clinical endocrinology and metabolism.

[71]  W. Whitmore.  Natural history and staging of prostate cancer. , 1984, The Urologic clinics of North America.